BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Cell Matrix Inc. (Acquired By CancerVax) 

1929 Zonal Avenue

Los Angeles  California  90033  U.S.A.
Phone: 323-343-8500 Fax: 323-343-8989


SEARCH JOBS
Cell Matrix Inc. (CMI) is rapidly building a leadership position in the discovery and development of inhibitors of angiogenesis. The company's lead products have been shown to be potent and highly selective inhibitors of angiogenesis, the process by which new blood vessels are formed to fuel the growth and metastasis of tumors.

CMI was founded in fall of 1999 by highly regarded scientists in the field of oncology and angiogenesis research to commercialize the recent discoveries of Peter C. Brooks, PhD as to the role of "cryptic" sites on extracellular matrix (ECM) proteins in the angiogenesis cascade. Dr. Brooks has shown that during tumor stimulated ECM remodeling, collagen denaturation exposes essential regulatory sites, which directly contribute to endothelial cell migration and new blood vessel growth.

CMI is developing monoclonal antibodies that target binding sites that are selectively exposed as a result of ECM remodeling. These antibodies have been shown to have therapeutic potential based on preclinical study results including:

  • Inhibition of new blood vessel growth
  • Inhibition of endothelial cell adhesion and migration
  • Selective staining of tumor associated blood vessels
  • Detection of elevated levels of denatured collagens in cancer patient serum
  • Inhibition of tumor growth
  • Inhibition of metastasis


CMI accomplishments in the identification of novel targets for angiogenesis regulation, discovery of molecules which block these targets, and the humanized antibody product development program have positioned CMI as a leader in drug discovery and development based on novel mechanisms of angiogenesis regulation.

Last Updated 7-10-01


 Key Statistics


Email: kcarner@cell-matrix.com
Ownership: Private

Web Site: Cell Matrix Inc. (Acquired By CancerVax)
Employees: 12
Symbol: 
 



Industry
Biotechnology


Collaborations

Eyetech Pharmaceuticals, Inc.  Opthalmic applications of antibodies to denatured collagen





 Company News
Currently No News Articles

//-->